Advertisement

Molecular Medicine

, Volume 18, Issue 1, pp 56–64 | Cite as

Interstitial Lung Disease and Pulmonary Fibrosis in Hermansky-Pudlak Syndrome Type 2, an Adaptor Protein-3 Complex Disease

  • Bernadette R. Gochuico
  • Marjan Huizing
  • Gretchen A. Golas
  • Charles D. Scher
  • Maria Tsokos
  • Stacey D. Denver
  • Melissa J. Frei-Jones
  • William A. Gahl
Research Article

Abstract

Pulmonary fibrosis develops in Hermansky-Pudlak syndrome (HPS) types 1 and 4. Limited information is available about lung disease in HPS type 2 (HPS-2), which is characterized by abnormal function of the adaptor protein-3 (AP-3) complex. To define lung disease in HPS-2, one child and two adults with HPS-2 were evaluated at the National Institutes of Health on at least two visits, and another child was evaluated at the University of Texas Health Science Center San Antonio. All four subjects with HPS-2 had findings of interstitial lung disease (ILD) on a high-resolution computed tomography scan of the chest. The predominant feature was ground glass opacification. Subject 1, a 14-year-old male, and subject 4, a 4-year-old male, had severe ILD, pulmonary fibrosis, secondary pulmonary hypertension and recurrent lung infections. Lung biopsy performed at 20 months of age in subject 1 revealed interstitial fibrosis and prominent type II pneumocyte hyperplasia without lamellar body enlargement. Subject 2, a 27-year-old male smoker, had mild ILD. Subject 3, a 22-year-old male nonsmoker and brother of subject 2, had minimal ILD. Severe impairment of gas exchange was found in subjects 1 and 4 and not in subjects 2 or 3. Plasma concentrations of transforming growth factor-β1 and interleukin-17A correlated with severity of HPS-2 ILD. These data show that children and young adults with HPS-2 and functional defects of the AP-3 complex are at risk for ILD and pulmonary fibrosis.

Notes

Acknowledgments

We thank Philip J Daroca, Jr, and the Electron Microscopy Laboratory of Tulane Medical Center for providing electron microscopy images. We also thank our patients who participated in this study for their contributions to this research. This study was supported by the Intramural Research Program of the National Human Genome Research Institute and the National Cancer Institute, National Institutes of Health, Bethesda, MD.

References

  1. 1.
    Huizing M, Helip-Wooley A, Westbroek W, Gunay-Aygun M, Gahl WA. (2008) Disorders of lysosome-related organelle biogenesis: clinical and molecular genetics. Annu. Rev. Genomics. Hum. Genet. 9:359–86.CrossRefGoogle Scholar
  2. 2.
    Gahl WA, et al. (1998) Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak syndrome). N. Engl. J. Med. 338:1258–64.CrossRefGoogle Scholar
  3. 3.
    Brantly M, et al. (2000) Pulmonary function and high-resolution CT findings in patients with an inherited form of pulmonary fibrosis, Hermansky-Pudlak syndrome, due to mutations in HPS-1. Chest. 117:129–36.CrossRefGoogle Scholar
  4. 4.
    Gahl WA, et al. (2002) Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol. Genet. Metab. 76:234–42.CrossRefGoogle Scholar
  5. 5.
    Nazarian R, Falcon-Pérez JM, Dell’Angelica EC. (2003) Biogenesis of lysosome-related organelles complex 3 (BLOC-3): a complex containing the Hermansky-Pudlak syndrome (HPS) proteins HPS1 and HPS4. Proc. Natl. Acad. Sci. U. S. A. 100:8770–5.CrossRefGoogle Scholar
  6. 6.
    Martina JA, Moriyama K, Bonifacino JS. (2003) BLOC-3, a protein complex containing the Hermansky-Pudlak syndrome gene products HPS1 and HPS4. J. Biol. Chem. 278:29376–84.CrossRefGoogle Scholar
  7. 7.
    Anderson PD, Huizing M, Claassen DA, White J, Gahl WA. (2003) Hermansky-Pudlak syndrome type 4 (HPS-4): clinical and molecular characteristics. Hum. Genet. 113:10–7.PubMedGoogle Scholar
  8. 8.
    Lederer DJ, et al. (2005) Successful bilateral lung transplantation for pulmonary fibrosis associated with the Hermansky-Pudlak syndrome. J Heart Lung Transplant. 24:1697–9.CrossRefGoogle Scholar
  9. 9.
    Thomas de Montpréville V, Mussot S, Dulmet E, Dartevelle P. (2006) Pulmonary fibrosis in Hermansky-Pudlak syndrome is not fully usual. Ann. Pathol. 26:445–9.CrossRefGoogle Scholar
  10. 10.
    Avila NA, et al. (2002) Hermansky-Pudlak syndrome: radiography and CT of the chest compared with pulmonary function tests and genetic studies. Am. J. Roentgenol. 179:887–92.CrossRefGoogle Scholar
  11. 11.
    Rouhani FN, et al. (2009) Alveolar macrophage dysregulation in Hermansky-Pudlak syndrome type-1. Am. J. Respir. Crit. Care Med. 180:1114–21.CrossRefGoogle Scholar
  12. 12.
    Dell’Angelica EC, Shotelersuk V, Aguilar RC, Gahl WA, Bonifacino JS. (1999) Altered trafficking of lysosomal proteins in Hermansky-Pudlak syndrome due to mutations in the beta 3A subunit of the AP-3 adaptor. Mol. Cell. 3:11–21.CrossRefGoogle Scholar
  13. 13.
    Huizing M, et al. (2002) Nonsense mutations in ADTB3A cause complete deficiency of the beta3A subunit of adaptor complex-3 and severe Hermansky-Pudlak syndrome type 2. Pediatr. Res. 51:150–8.CrossRefGoogle Scholar
  14. 14.
    Clark RH, et al. (2003) Adaptor protein 3-dependent microtubule-mediated movement of lytic granules to the immunological synapse. Nat. Immunol. 4:1111–20.CrossRefGoogle Scholar
  15. 15.
    Dell’Angelica EC. (2009) AP-3-dependent trafficking and disease: the first decade. Curr. Opin. Cell. Biol. 21:552–9.CrossRefGoogle Scholar
  16. 16.
    Fontana S, et al. (2006) Innate immunity defects in Hermansky-Pudlak type 2 syndrome. Blood. 107:4857–64.CrossRefGoogle Scholar
  17. 17.
    Enders A, et al. (2006) Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II. Blood. 108:81–7.CrossRefGoogle Scholar
  18. 18.
    Jung J, et al. (2006) Identification of a homozygous deletion in the AP3B1 gene causing Hermansky-Pudlak syndrome, type 2. Blood. 108:362–9.CrossRefGoogle Scholar
  19. 19.
    Wenham M, et al. (2010) Two patients with Hermansky Pudlak syndrome type 2 and novel mutations in AP3B1. Haematologica. 95:333–7.CrossRefGoogle Scholar
  20. 20.
    Chiang PW, Spector E, Thomas M, Frei-Jones M. (2010) Novel mutation causing Hermansky-Pudlak syndrome type 2. Pediatr. Blood Cancer. 55:1438.CrossRefGoogle Scholar
  21. 21.
    Shotelersuk V, Dell’Angelica EC, Hartnell L, Bonifacino JS, Gahl WA. (2000) A new variant of Hermansky-Pudlak syndrome due to mutations in a gene responsible for vesicle formation. Am. J. Med. 108:423–7.CrossRefGoogle Scholar
  22. 22.
    Feng L, et al. (1999) The β3A subunit gene (Ap3b1) of the AP-3 adaptor complex is altered in the mouse hypopigmentation mutant pearl, a model for Hermansky-Pudlak syndrome and night blindness. Hum. Mol. Genet. 8:323–30.CrossRefGoogle Scholar
  23. 23.
    Young LR, Pasula R, Gulleman PM, Deutsch GH, McCormack FX. (2007) Susceptibility of Hermansky-Pudlak mice to bleomycin-induced type II cell apoptosis and fibrosis. Am. J. Respir. Cell Mol. Biol. 37:67–74.CrossRefGoogle Scholar
  24. 24.
    Miller MR, et al. (2005) Standardisation of spirometry. Eur. Respir. J. 26:319–38.CrossRefGoogle Scholar
  25. 25.
    Wanger J, et al. (2005) Standardisation of the measurement of lung volumes. Eur. Respir. J. 26:511–22.CrossRefGoogle Scholar
  26. 26.
    ATS Statement. (2002) Guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 166:111–7.CrossRefGoogle Scholar
  27. 27.
    ATS Workshop Proceedings. (2006) Exhaled nitric oxide and nitric oxide oxidative metabolism in exhaled breath condensate. Proc. Am. Thorac. Soc. 3:131–45.CrossRefGoogle Scholar
  28. 28.
    Roberts A, et al. (1986) Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl. Acad. Sci. U. S. A. 83:4167–71.CrossRefGoogle Scholar
  29. 29.
    Wilson MS, et al. (2010) Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J. Exp. Med. 207:535–52.CrossRefGoogle Scholar
  30. 30.
    Tang YW, et al. (2003) Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J. Clin. Microbiol. 41:2633–40.CrossRefGoogle Scholar
  31. 31.
    Touw CML, et al. (2010) Detection of pulmonary complications in common variable immunodeficiency. Pediatr. Allergy Immunol. 21:793–805.CrossRefGoogle Scholar
  32. 32.
    Tang X, Yamanaka S, Miyagi Y, Nagashima Y, Nakatani Y. (2005) Lung pathology of pale ear mouse (model of Hermansky-Pudlak syndrome 1) and beige mouse (model of Chediak-Higashi syndrome): severity of giant lamellar body degeneration of type II pneumocytes correlates with interstitial inflammation. Pathol. Int. 55:137–43.CrossRefGoogle Scholar
  33. 33.
    Young LR, Borchers MT, Allen HL, Gibbons RS, McCormack FX. (2006) Lung-restricted macrophage activation in the pearl mouse model of Hermansky-Pudlak syndrome. J. Immunol. 176:4361–8.CrossRefGoogle Scholar
  34. 34.
    Nakatani Y, et al. (2000) Interstitial pneumonia in Hermansky-Pudlak syndrome: significance of florid foamy swelling/degeneration (giant lamellar body degeneration) of type-2 pneumocytes. Virchows Arch. 437:304–13.CrossRefGoogle Scholar
  35. 35.
    Lyerla TA, et al. (2003) Aberrant lung structure, composition, and function in a murine model of Hermansky-Pudlak syndrome. Am. J. Physiol. Lung Cell Mol. Physiol. 285:L643–53.CrossRefGoogle Scholar
  36. 36.
    Guttentag SH, et al. (2005) Defective surfactant secretion in a mouse model of Hermansky-Pudlak syndrome. Am. J. Respir. Cell Mol. Biol. 33:14–21.CrossRefGoogle Scholar
  37. 37.
    Wang L, Lyerla T. (2010) Histochemical and cellular changes accompanying the appearance of lung fibrosis in an experimental mouse model for Hermansky Pudlak syndrome. Histochem. Cell Biol. 134:205–13.CrossRefGoogle Scholar
  38. 38.
    Mahavadi P, et al. (2010) Epithelial stress and apoptosis underlie Hermansky-Pudlak syndrome associated interstitial pneumonia. Am. J. Respir. Crit. Care Med. 182:207–19.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2012

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Bernadette R. Gochuico
    • 1
  • Marjan Huizing
    • 1
  • Gretchen A. Golas
    • 2
    • 3
  • Charles D. Scher
    • 4
  • Maria Tsokos
    • 5
  • Stacey D. Denver
    • 6
  • Melissa J. Frei-Jones
    • 6
  • William A. Gahl
    • 1
    • 2
    • 3
  1. 1.Section on Human Biochemical Genetics, Medical Genetics BranchNational Human Genome Research Institute, National Institutes of HealthBethesdaUSA
  2. 2.Office of the Clinical DirectorNational Human Genome Research Institute, National Institutes of HealthBethesdaUSA
  3. 3.Office of Rare Diseases ResearchNational Institutes of HealthBethesdaUSA
  4. 4.Section of Hematology-Oncology, Department of PediatricsTulane University School of MedicineNew OrleansUSA
  5. 5.Laboratory of Pathology, National Cancer InstituteNational Institutes of HealthBethesdaUSA
  6. 6.The University of Texas Health Science Center San AntonioSan AntonioUSA

Personalised recommendations